OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives
Robert Jenke, Nina Reßing, Finn K. Hansen, et al.
Cancers (2021) Vol. 13, Iss. 4, pp. 634-634
Open Access | Times Cited: 137
Robert Jenke, Nina Reßing, Finn K. Hansen, et al.
Cancers (2021) Vol. 13, Iss. 4, pp. 634-634
Open Access | Times Cited: 137
Showing 1-25 of 137 citing articles:
Targeting epigenetic regulators to overcome drug resistance in cancers
Nan Wang, Ting Ma, Bin Yu
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 147
Nan Wang, Ting Ma, Bin Yu
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 147
How epigenetics impacts on human diseases
Antonella Farsetti, Barbara Illi, Carlo Gaetano
European Journal of Internal Medicine (2023) Vol. 114, pp. 15-22
Open Access | Times Cited: 51
Antonella Farsetti, Barbara Illi, Carlo Gaetano
European Journal of Internal Medicine (2023) Vol. 114, pp. 15-22
Open Access | Times Cited: 51
Recent histone deacetylase inhibitors in cancer therapy
Roza Parveen, Divya Harihar, Biswa Prasun Chatterji
Cancer (2023) Vol. 129, Iss. 21, pp. 3372-3380
Closed Access | Times Cited: 49
Roza Parveen, Divya Harihar, Biswa Prasun Chatterji
Cancer (2023) Vol. 129, Iss. 21, pp. 3372-3380
Closed Access | Times Cited: 49
HDAC-targeting epigenetic modulators for cancer immunotherapy
Binbin Cheng, Wei Pan, Yao Xiao, et al.
European Journal of Medicinal Chemistry (2024) Vol. 265, pp. 116129-116129
Closed Access | Times Cited: 31
Binbin Cheng, Wei Pan, Yao Xiao, et al.
European Journal of Medicinal Chemistry (2024) Vol. 265, pp. 116129-116129
Closed Access | Times Cited: 31
Topological indices and QSPR modeling of some novel drugs used in the cancer treatment
Özge Çolakoğlu Havare
International Journal of Quantum Chemistry (2021) Vol. 121, Iss. 24
Closed Access | Times Cited: 70
Özge Çolakoğlu Havare
International Journal of Quantum Chemistry (2021) Vol. 121, Iss. 24
Closed Access | Times Cited: 70
A bibliometric analysis of PROTAC from 2001 to 2021
Deping Li, Dongmin Yu, Yan Li, et al.
European Journal of Medicinal Chemistry (2022) Vol. 244, pp. 114838-114838
Closed Access | Times Cited: 65
Deping Li, Dongmin Yu, Yan Li, et al.
European Journal of Medicinal Chemistry (2022) Vol. 244, pp. 114838-114838
Closed Access | Times Cited: 65
HDAC Inhibitors: Innovative Strategies for Their Design and Applications
Mateusz Daśko, Beatriz de Pascual‐Teresa, Irene Ortín, et al.
Molecules (2022) Vol. 27, Iss. 3, pp. 715-715
Open Access | Times Cited: 44
Mateusz Daśko, Beatriz de Pascual‐Teresa, Irene Ortín, et al.
Molecules (2022) Vol. 27, Iss. 3, pp. 715-715
Open Access | Times Cited: 44
PROTACs: Novel tools for improving immunotherapy in cancer
Shizhe Li, Ting Chen, Jinxin Liu, et al.
Cancer Letters (2023) Vol. 560, pp. 216128-216128
Closed Access | Times Cited: 25
Shizhe Li, Ting Chen, Jinxin Liu, et al.
Cancer Letters (2023) Vol. 560, pp. 216128-216128
Closed Access | Times Cited: 25
Difluoromethyl-1,3,4-oxadiazoles Are Selective, Mechanism-Based, and Essentially Irreversible Inhibitors of Histone Deacetylase 6
Beate König, P. R. Watson, Nina Reßing, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 19, pp. 13821-13837
Open Access | Times Cited: 24
Beate König, P. R. Watson, Nina Reßing, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 19, pp. 13821-13837
Open Access | Times Cited: 24
Emerging therapeutic strategies in cancer therapy by HDAC inhibition as the chemotherapeutic potent and epigenetic regulator
Dipanjan Karati, Swarupananda Mukherjee, Souvik Roy
Medical Oncology (2024) Vol. 41, Iss. 4
Closed Access | Times Cited: 11
Dipanjan Karati, Swarupananda Mukherjee, Souvik Roy
Medical Oncology (2024) Vol. 41, Iss. 4
Closed Access | Times Cited: 11
HDAC inhibitors activate lipid peroxidation and ferroptosis in gastric cancer
Robert Jenke, Denys Oliinyk, Tamara Zenz, et al.
Biochemical Pharmacology (2024) Vol. 225, pp. 116257-116257
Open Access | Times Cited: 8
Robert Jenke, Denys Oliinyk, Tamara Zenz, et al.
Biochemical Pharmacology (2024) Vol. 225, pp. 116257-116257
Open Access | Times Cited: 8
Tailored therapies for triple-negative breast cancer: current landscape and future perceptions
Yumna Khan, Sana Rizvi, Ali Raza, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Closed Access | Times Cited: 1
Yumna Khan, Sana Rizvi, Ali Raza, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Closed Access | Times Cited: 1
HDAC Inhibitors: Dissecting Mechanisms of Action to Counter Tumor Heterogeneity
Dimitris Karagiannis, Θεόδωρος Ράμπιας
Cancers (2021) Vol. 13, Iss. 14, pp. 3575-3575
Open Access | Times Cited: 54
Dimitris Karagiannis, Θεόδωρος Ράμπιας
Cancers (2021) Vol. 13, Iss. 14, pp. 3575-3575
Open Access | Times Cited: 54
The Role of Notch3 Signaling in Cancer Stemness and Chemoresistance: Molecular Mechanisms and Targeting Strategies
Mengxi Xiu, Yongbo Wang, Baoli Li, et al.
Frontiers in Molecular Biosciences (2021) Vol. 8
Open Access | Times Cited: 49
Mengxi Xiu, Yongbo Wang, Baoli Li, et al.
Frontiers in Molecular Biosciences (2021) Vol. 8
Open Access | Times Cited: 49
H3K36 trimethylation-mediated biological functions in cancer
Xiao Chu, Tao Fan, He Tian, et al.
Clinical Epigenetics (2021) Vol. 13, Iss. 1
Open Access | Times Cited: 44
Xiao Chu, Tao Fan, He Tian, et al.
Clinical Epigenetics (2021) Vol. 13, Iss. 1
Open Access | Times Cited: 44
Epigenetic Dysregulations in Merkel Cell Polyomavirus-Driven Merkel Cell Carcinoma
John Charles Rotondo, Chiara Mazziotta, Carmen Lanzillotti, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 21, pp. 11464-11464
Open Access | Times Cited: 43
John Charles Rotondo, Chiara Mazziotta, Carmen Lanzillotti, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 21, pp. 11464-11464
Open Access | Times Cited: 43
Targeting Histone Deacetylases: Opportunities for Cancer Treatment and Chemoprevention
Dušan Ružić, Nemanja Djoković, Tatjana Srdić‐Rajić, et al.
Pharmaceutics (2022) Vol. 14, Iss. 1, pp. 209-209
Open Access | Times Cited: 37
Dušan Ružić, Nemanja Djoković, Tatjana Srdić‐Rajić, et al.
Pharmaceutics (2022) Vol. 14, Iss. 1, pp. 209-209
Open Access | Times Cited: 37
Current trends in development of HDAC-based chemotherapeutics
Narges Cheshmazar, Maryam Hamzeh‐Mivehroud, Hojjatollah Nozad Charoudeh, et al.
Life Sciences (2022) Vol. 308, pp. 120946-120946
Closed Access | Times Cited: 34
Narges Cheshmazar, Maryam Hamzeh‐Mivehroud, Hojjatollah Nozad Charoudeh, et al.
Life Sciences (2022) Vol. 308, pp. 120946-120946
Closed Access | Times Cited: 34
HDAC Inhibitors for the Therapy of Triple Negative Breast Cancer
Cristina Maccallini, Alessandra Ammazzalorso, Barbara De Filippis, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 6, pp. 667-667
Open Access | Times Cited: 33
Cristina Maccallini, Alessandra Ammazzalorso, Barbara De Filippis, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 6, pp. 667-667
Open Access | Times Cited: 33
Development of the first non-hydroxamate selective HDAC6 degraders
Tim Keuler, Beate König, Nico Bückreiß, et al.
Chemical Communications (2022) Vol. 58, Iss. 79, pp. 11087-11090
Closed Access | Times Cited: 29
Tim Keuler, Beate König, Nico Bückreiß, et al.
Chemical Communications (2022) Vol. 58, Iss. 79, pp. 11087-11090
Closed Access | Times Cited: 29
Are inhibitors of histone deacetylase 8 (HDAC8) effective in hematological cancers especially acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL)?
Sk. Abdul Amin, Samima Khatun, Shovanlal Gayen, et al.
European Journal of Medicinal Chemistry (2023) Vol. 258, pp. 115594-115594
Closed Access | Times Cited: 19
Sk. Abdul Amin, Samima Khatun, Shovanlal Gayen, et al.
European Journal of Medicinal Chemistry (2023) Vol. 258, pp. 115594-115594
Closed Access | Times Cited: 19
Chalcones and Gastrointestinal Cancers: Experimental Evidence
Radka Michalková, Martin Kello, Martina Čižmáriková, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 6, pp. 5964-5964
Open Access | Times Cited: 18
Radka Michalková, Martin Kello, Martina Čižmáriková, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 6, pp. 5964-5964
Open Access | Times Cited: 18
Sensitizing cancer cells to immune checkpoint inhibitors by microbiota-mediated upregulation of HLA class I
Valentina Ferrari, Antonino Lo Cascio, Alessia Melacarne, et al.
Cancer Cell (2023) Vol. 41, Iss. 10, pp. 1717-1730.e4
Open Access | Times Cited: 18
Valentina Ferrari, Antonino Lo Cascio, Alessia Melacarne, et al.
Cancer Cell (2023) Vol. 41, Iss. 10, pp. 1717-1730.e4
Open Access | Times Cited: 18
Recent advancement of HDAC inhibitors against breast cancer
Syed Abdulla Mehmood, Kantrol Kumar Sahu, Sounok Sengupta, et al.
Medical Oncology (2023) Vol. 40, Iss. 7
Closed Access | Times Cited: 17
Syed Abdulla Mehmood, Kantrol Kumar Sahu, Sounok Sengupta, et al.
Medical Oncology (2023) Vol. 40, Iss. 7
Closed Access | Times Cited: 17
Targeting bacterial metabolites in tumor for cancer therapy: An alternative approach for targeting tumor-associated bacteria
Guofeng Ji, Jingjing Zhao, Xinghui Si, et al.
Advanced Drug Delivery Reviews (2024) Vol. 211, pp. 115345-115345
Closed Access | Times Cited: 7
Guofeng Ji, Jingjing Zhao, Xinghui Si, et al.
Advanced Drug Delivery Reviews (2024) Vol. 211, pp. 115345-115345
Closed Access | Times Cited: 7
